

## ■ DETAILED CONTENTS

<b>1</b>	<b>Introduction</b>	<b>1</b>
1.1	What is cancer?	2
1.2	Evidence suggests that cancer is a disease of the genome at the cellular level	5
1.3	Influential factors in human carcinogenesis	10
1.4	Principles of conventional cancer therapies	13
1.5	Clinical trials	15
1.6	The role of molecular targets in cancer therapies	16
<b>2</b>	<b>DNA structure and stability: mutations versus repair</b>	<b>21</b>
2.1	Gene structure—two parts of a gene: the regulatory region and the coding region	22
2.2	Mutations	23
2.3	Carcinogenic agents	25
2.4	DNA repair and predispositions to cancer	38
	⊙ Therapeutic strategies	42
2.5	Conventional therapies: chemotherapy and radiation therapy	42
2.6	Strategies that target DNA repair pathways	47
<b>3</b>	<b>Regulation of gene expression</b>	<b>53</b>
3.1	Transcription factors and transcriptional regulation	53
3.2	Chromatin structure	59
3.3	Epigenetic regulation of transcription	60
3.4	Evidence of a role for epigenetics in carcinogenesis	63
3.5	Telomeres and telomerase	66
3.6	MicroRNAs (miRNAs) and regulation of mRNA expression	69
	⊙ Therapeutic strategies	70
3.7	Epigenomic and histonomic drugs	70
3.8	Telomerase inhibitors	72
<b>4</b>	<b>Growth factor signaling and oncogenes</b>	<b>77</b>
4.1	Epidermal growth factor signaling: an important paradigm	77
4.2	Oncogenes	86

⊙ Therapeutic strategies	95
4.3 Kinases as drug targets	95
<b>5 The cell cycle</b>	<b>103</b>
5.1 Cyclins and cyclin-dependent kinases (cdks)	104
5.2 Mechanisms of cdk regulation	107
5.3 Progression through the G <sub>1</sub> checkpoint	109
5.4 The G <sub>2</sub> checkpoint	111
5.5 The mitotic checkpoint	112
5.6 The cell cycle and cancer	114
⊙ Therapeutic strategies	117
5.7 Cyclin-dependent kinase inhibitors	117
5.8 Other cell cycle kinase targets	118
5.9 Inhibitors of the mitotic spindle	118
<b>6 Growth inhibition and tumor suppressor genes</b>	<b>123</b>
6.1 Definitions of tumor suppressor genes	123
6.2 The retinoblastoma gene	127
6.3 Mutations in the RB pathway and cancer	129
6.4 The p53 pathway	129
6.5 Mutations in the p53 pathway and cancer	137
6.6 Interaction of DNA viral protein products with RB and p53	139
⊙ Therapeutic strategies	141
6.7 Targeting of the p53 pathway	141
<b>7 Apoptosis</b>	<b>149</b>
7.1 Molecular mechanisms of apoptosis	150
7.2 Apoptosis and cancer	160
7.3 Apoptosis and chemotherapy	164
⊙ Therapeutic strategies	165
7.4 Apoptotic drugs	165
<b>8 Stem cells and differentiation</b>	<b>173</b>
8.1 Stem cells and cancer	174
8.2 Differentiation and the regulation of transcription	184
⊙ Therapeutic strategies	189
8.3 Inhibitors of the Wnt pathway	190
8.4 Inhibitors of the Hh pathway	191
8.5 Leukemia and differentiation therapies	192

<b>9</b>	<b>Metastasis</b>	<b>197</b>
9.1	The process of metastasis	198
9.2	Tools of cell invasion: cell adhesion molecules, integrins, and proteases	199
9.3	Intravasation	203
9.4	Transport	203
9.5	Extravasation	204
9.6	Metastatic colonization	205
9.7	Angiogenesis	206
9.8	Other means of tumor neovascularization	212
	⊗ Therapeutic strategies	212
9.9	Metalloproteinase inhibitors (MPIs)	213
9.10	Strategies for restoring metastasis suppressors	214
9.11	Anti-angiogenic therapy and vascular targeting	214
9.12	Targeting several steps of metastasis at once	220
<b>10</b>	<b>The immune system, infections, and inflammation</b>	<b>225</b>
10.1	The immune system and cancer	226
10.2	Identifying infectious agents as carcinogens	230
10.3	Inflammation and cancer	237
	⊗ Therapeutic strategies	243
10.4	A national vaccination program against hepatitis B virus in Taiwan	244
10.5	Eradication of <i>H. pylori</i> and the relationship to prevention of gastric cancer	244
10.6	Cancer vaccines to prevent cervical cancer	245
10.7	Inhibition of inflammation	246
<b>11</b>	<b>Nutrients, hormones, and gene interactions</b>	<b>253</b>
11.1	Causative factors	255
11.2	Preventative factors: microconstituents of fruits and vegetables	259
11.3	Reprogramming energy metabolism in tumor cells—an emerging hallmark of cancer	265
11.4	Genetic polymorphisms and diet	268
11.5	Vitamin D: a link between nutrients and hormone action	269
11.6	Hormones and cancer	271
	⊗ Therapeutic strategies	274
11.7	“Enhanced” foods and dietary supplements for chemoprevention	274
11.8	Drugs that target energy pathways	276
11.9	Drugs that target estrogen	276

<b>12</b>	<b>The cancer industry: drug development, pharmacogenomics, and clinical trial design</b>	<b>283</b>
12.1	Strategies of drug development	283
12.2	Development of imatinib	287
12.3	Second- and third-generation therapeutics	288
12.4	Pharmacogenomics	290
12.5	Improved clinical trial design	292
12.6	A career in cancer research	295
<b>13</b>	<b>Cancer in the future: focus on cancer vaccines and technology</b>	<b>299</b>
13.1	Cancer vaccines	300
13.2	Microarrays and gene expression profiling	306
13.3	Diagnostics and prognostics	308
13.4	Imaging	310
13.5	Personalized medicine and bioinformatics	311
13.6	Cancer nanotechnology	313
13.7	Treating cancer symptoms	314
13.8	Are we making progress?	315
	APPENDIX 1: CELL CYCLE REGULATION	321
	APPENDIX 2: CENTERS FOR CANCER RESEARCH	323
	GLOSSARY	327
	INDEX	337